Are PSA density and PSA density of the transition zone more accurate than PSA in predicting the pathological stage of clinically localized prostate cancer?

Giannarini, Gianluca; Scott, Cathryn A.; Moro, U; Pertoldi, Barbara; Beltrami, Carlo Alberto; Selli, Cesare

doi:10.1016/j.urolonc.2007.04.002

Cited by 18 publications

(13 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, factors such as race or ethnicity may significantly affect PSA values, even after adjustment for age and prostate volume (27)(28)(29). A number of studies have also demonstrated that a high GS is useful for predicting extraprostatic extension (30)(31)(32), and the present findings were consistent with these findings. As CFL1 expression was an independent prognostic factor in PCa, immunohistochemical detection of this marker in cancer tissue samples may aid in decision making.…”

Section: A B a B C D Esupporting

confidence: 84%

Overexpression of cofilin 1 in prostate cancer and the corresponding clinical implications

Lü

Luo

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. Cofilin 1 (CFL1) is a cytoskeletal protein and overexpression of the protein has been associated with aggressiveness in certain types of malignancies. The aim of the present study was to investigate the clinical implications of CFL1 expression in prostate cancer (PCa). Immunohistochemical analysis was performed using formalin-fixed paraffin-embedded tissue sections obtained from 111 patients with PCa and 47 patients with benign prostatic hyperplasia (BPH). In total, 78 (70.3%) out of 111 PCa tissues were found to express the CFL1 protein, while no expression was detected in BPH tissues. In addition, CFL1 was also observed to be significantly associated with the Gleason score (GS; <7 vs. ≥7; P<0.0001) and presence of lymph node metastasis (presence vs. absence; P<0.0001). However, there was no association between the expression of CFL1 and other clinicopathological variables, such as age (<69 years vs. ≥69 years; P= 0.54), pre-operative prostate specific antigen level (<20 ng/ml vs. ≥20 ng/ml; P= 0.45) and pathological stage (T2 vs. ≥T3a; P= 0.055). In addition, 35 tissues (31.5%) were observed to possess a CFL1-positive mesenchyme. CFL1 expression was revealed to be an independent predictive factor for a high GS. The status of CFL1 expression in the mesenchyme also found to individually predict extraprostatic extension in PCa patients, based on multivariate analysis. The results of the present study indicated that CFL1 may specifically predict the development of PCa, and that the expression of CFL1 in the mesenchyme may be closely associated with the development of lymph node metastasis. IntroductionProstate cancer (PCa) is one of the most common non-cutaneous malignancies in males. Since the introduction of the prostate specific antigen (PSA)-based screening strategy in clinical practice, a marked increase in the incidence of PCa has been observed (1). Although the use of this screening strategy has resulted in a 40% reduction in PCa-associated mortality, the majority of patients succumb to the disease once metastasis has occurred. In addition, overtreatment of indolent PCa has emerged. This phenomenon may account for the deficiencies in accurate diagnosis and risk stratification. Therefore, the identification and validation of novel biomarkers for PCa should be considered a priority (2).Cofilin 1 (CFL1) is the non-muscle isoform of the product of the CFL1 gene (Gene ID, 1072). CFL1 is a small ubiquitous protein that is able to bind monomeric globular (G) and filamentous actin and inhibits the polymerization of monomeric G-actin in a pH-dependent manner (3), playing a key role in cell migration and cytokinesis (4). This protein is reported to be directly associated with the invasion, metastasis and chemoresistance of various human malignant solid tumors (5,6). However, no previous studies regarding CFL1 expression and its association with clinicopathological features in PCa are available in the literature. The expression of CFL1 and its clinical implications in PCa are investigated in the present stud...

show abstract

Section: A B a B C D Esupporting

confidence: 84%

Overexpression of cofilin 1 in prostate cancer and the corresponding clinical implications

Lü

Luo

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…The findings also demonstrated that ERG rearrangement had a similar AUC as biopsy GS (0.781 vs. 0.763); furthermore, multivariate logistic regression models revealed that biopsy GSs of 7 and ≥8 were independent factors for EPE, which is consistent with prior publications (12,(38)(39)(40).…”

Section: Discussionsupporting

confidence: 88%

ERG rearrangement as a novel marker for predicting the extra-prostatic extension of clinically localised prostate cancer

Zhang

Pang

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Currently, there are no well-established preoperative clinicopathological parameters for predicting extra-prostatic extension (EPE) in patients with clinically localised prostate cancer (PCa). The transmembrane protease serine 2 (TMPRSS2)-ETS-related gene (ERG) fusion gene is a specific biomarker of PCa and is considered a prognostic predictor. The aim of the present study was to assess the value of this marker for predicting EPE in patients with clinically localised PCa. In total, 306 PCa patients with clinically localised disease, including 220 patients (71.9%) with organ-confined disease and 86 EPE cases (28.1%), were included in the study. Receiver operating characteristic curves and logistic regression were employed to establish the optimal cut-off value and to investigate whether ERG rearrangement was an independent predictor for the EPE of clinically localised PCa. A leave-one-out cross-validation (LOOCV) model was implemented to validate the predictive power of ERG rearrangement. An increase in ERG rearrangements was identified to be associate`d with EPE, and the optimal cut-off for predicting EPE was determined to be 2.25%, with a sensitivity of 70.24% [95% confidence interval (CI), 62.6-78.9%], a specificity of 80. 43% (95% CI,, and an area under the curve (AUC) of 0.781 (95% CI,. In the LOOCV model, ERG rearrangement also demonstrated good performance for predicting EPE (sensitivity, 76.923%; specificity, 71.429%; 95% CI for AUC, 0.724-0.958). In addition, a high Gleason score (≥7) and a cT2c classification upon biopsy were independent factors for EPE.

show abstract

“…There are several studies that have shown other prognostic parameters are useful for predicting ECE in addition to tPSA [17,31,32.] PSAD is one of them and has been reported to be more specific than tPSA for the detection of prostate cancer [18,31].…”

Section: Discussionmentioning

confidence: 99%

“…PSAD is one of them and has been reported to be more specific than tPSA for the detection of prostate cancer [18,31]. Magheli et al [18] demonstrated that for men with biopsy Gleason scores ≥7, PSAD was equal to tPSA for the prediction of ECE, while PSAD exhibited a higher AUC than tPSA in patients with biopsy Gleason score ≤6.…”

Section: Discussionmentioning

confidence: 99%

“…Magheli et al [18] demonstrated that for men with biopsy Gleason scores ≥7, PSAD was equal to tPSA for the prediction of ECE, while PSAD exhibited a higher AUC than tPSA in patients with biopsy Gleason score ≤6. Giannarini et al [31] demonstrated that the combination of Gleason score and percentage of positive biopsy cores with either tPSA or PSAD had the same predictive results for ECE. However, the results are still contradictory.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prediction of Extraprostatic Extension in Patients with Clinically Organ-Confined Prostate Cancer

Lin

Zhang²,

Li³

et al. 2013

Urol Int

View full text Add to dashboard Cite

Introduction: Preoperative parameters for predicting extraprostatic extension (ECE) in clinically organ-confined prostate cancer patients are not well defined. Our aim was to evaluate the roles of the biopsy Gleason score, prostate-specific antigen (PSA)-based parameters, volume, and clinical T classification in prediction of ECE. Materials and Methods: A total of 188 patients with clinically organ-confined prostate cancer who underwent radical prostatectomy from January 1998 to December 2007 were included in the study. Age, prostate volume, preoperative total serum PSA (tPSA), free PSA, PSA density (PSAD), biopsy Gleason score, and clinical T classification were analyzed by univariate and multivariate analyses to predict ECE. Results: Pathologic examination revealed 130 patients had organ-confined disease and 58 patients were positive for ECE. Multivariate logistic regression analyses showed that tPSA was an independent predictor of ECE. Gleason score ≥8 had a trend for predicting ECE. Receiver operating characteristic (ROC) curves suggested that tPSA and PSAD had a similar diagnosis performance in the whole cohort. For patients with Gleason score of 7, PSAD was found to be statistically better than tPSA for predicting ECE. Conclusions: tPSA remains one of the most important factors for predicting ECE in prostate cancer patients. PSAD may be more helpful than tPSA for predicting ECE in the patients with Gleason score of 7.

show abstract

Are PSA density and PSA density of the transition zone more accurate than PSA in predicting the pathological stage of clinically localized prostate cancer?

Cited by 18 publications

References 29 publications

Overexpression of cofilin 1 in prostate cancer and the corresponding clinical implications

Overexpression of cofilin 1 in prostate cancer and the corresponding clinical implications

ERG rearrangement as a novel marker for predicting the extra-prostatic extension of clinically localised prostate cancer

Prediction of Extraprostatic Extension in Patients with Clinically Organ-Confined Prostate Cancer

Contact Info

Product

Resources

About